J. Delattre

Centre National de la Recherche Scientifique — France

Medicine · Health Sciences

18h-index1.3kcitations72works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Glioma Diagnosis and Treatment(37), Brain Metastases and Treatment(11), Meningioma and schwannoma management(6), Cancer, Hypoxia, and Metabolism(5), Antioxidant Activity and Oxidative Stress(4)

Publications72 total

PL1.1 CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDHmutant gliomas
Neuro-Oncology·2019· 117 citedOpen Access
P04.12 Characteristics of IDH-mutant gliomas with non-canonical IDH mutations
Neuro-Oncology·2019Open Access
La biopsie cérébrale en médecine interne : un acte sûr et rentable
La Revue de Médecine Interne·2019
OS11.3 Machine learning for better prognostic stratification and driver genes identification in 1p/19q-codeleted grade III gliomas
Neuro-Oncology·2017· 2 citedOpen Access
P09.14 Clonal and subclonal evolution of 1p/19q co-deleted oligodendrogliomas
Neuro-Oncology·2016Open Access
P06.19 TERT promoter mutation is an independent prognostic factor in 1p/19q co-deleted oligodendrogliomas: a POLA network study
Neuro-Oncology·2016Open Access
Prediction of Response to Temozolomide in Low‐Grade Glioma Patients Based on Tumor Size Dynamics and Genetic Characteristics
CPT Pharmacometrics & Systems Pharmacology·2015· 26 citedOpen Access
O8.04 * TEMOZOLOMIDE AFTER RADIOTHERAPY IN RECURRENT "LOW-GRADE" DIFFUSE BRAINSTEM GLIOMA IN ADULTS
Neuro-Oncology·2014Open Access
P17.01 * CHROMOSOME ARM 9P LOSS OF HETEROZYGOSITY IS A MARKER OF SHORTER SURVIVAL IN 1P/19Q CO-DELETED ANAPLASTIC OLIGODENDROGLIOMA. A POLA NETWORK STUDY
Neuro-Oncology·2014Open Access
Central Nervous System Complications in Patients Undergoing Chemotherapy
Medical radiology·2014· 1 cited
Glioma tumor grade correlates with parkin depletion in mutant p53-linked tumors and results from loss of function of p53 transcriptional activity
Oncogene·2013· 62 cited
LONG TERM FOLLOW-UP RESULTS OF EORTC 26951: A RANDOMIZED PHASE III STUDY ON ADJUVANT PCV CHEMOTHERAPY IN ANAPLASTIC OLIGODENDROGLIAL TUMORS - A REPORT OF THE EORTC BRAIN TUMOR GROUP
Data Archiving and Networked Services (DANS)·2012· 1 cited
802 ORAL Epigenetic Markers Identify MGMT-methylated Glioblastoma Poorly Responding to Combined Radiotherapy-temozolomide (Stupp Regimen)
European Journal of Cancer·2011
TEMOBIC: A ANOCEF phase II study of BCNU and temozolomide (TMZ) combination prior to radiotherapy (RT) in anaplasic oligodendroglial gliomas (AOG).
Journal of Clinical Oncology·2011· 2 cited
Évaluation de la fatigue dans les glioblastomes en récidive traités par l’association irinotécan-bévacizumab
Revue Neurologique·2011· 4 cited
Predictive impact of <i>IDH1</i> or <i>IDH2</i> mutations on outcome and response to temozolomide in low-grade gliomas.
Journal of Clinical Oncology·2010· 3 cited
Supratentorial low-grade gliomas in older patients
Neurology·2009· 58 cited
Bevacizumab and irinotecan for recurrent oligodendroglial tumors
Neurology·2009· 71 cited
α-Internexin expression identifies 1p19q codeleted gliomas
Neurology·2009· 51 cited
Méningite chronique à méningocoque de l’adulte
Revue Neurologique·2008· 5 cited
page 1 of 4Next →

Frequent Co-authors

Khê Hoang‐Xuan(14), Marc Sanson(12), Karima Mokhtari(10), Y. Marie(8), Dominique Bonnefont‐Rousselot(8), Caroline Dehais(6), Ahmed Idbaïh(6), M Poisson(6), G. Boisserie(6), F Baillet(6), Sophie Taillibert(5), Hugues Duffau(5), François Ducray(5), Thierry Faillot(5), Jacqueline Peynet(5), M. Kujas(4), Emmanuelle Crinière(4), Alain Carpentier(4), Philippe Cornu(4), Dimitri Psimaras(4)